PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy

Polymeric micelles have attracted considerable attention for effective delivery of poorly water-soluble cancer drugs. Polyethylene glycol (PEG), which has been approved for human use by the US Food and Drug Administration, is the most commonly used hydrophilic component of polymeric micelles because...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 10; p. 808
Main Authors Li, Yanping, Zhang, Ting, Liu, Qinhui, He, Jinhan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 19.07.2019
Subjects
cancer immunochemotherapy
cancer therapy
drug loading capacity
dual-functional nanomicelles
multidrug resistance
Pharmacology
polyethylene glycol (PEG)
cancer immunochemotherapy
cancer therapy
multidrug resistance
dual-functional nanomicelles
polyethylene glycol (PEG)
drug loading capacity
Online AccessGet full text

Cover

More Information
Summary:Polymeric micelles have attracted considerable attention for effective delivery of poorly water-soluble cancer drugs. Polyethylene glycol (PEG), which has been approved for human use by the US Food and Drug Administration, is the most commonly used hydrophilic component of polymeric micelles because it is biocompatible and biodegradable. One disadvantage of traditional polymeric micelles is that they include a large amount of inert carrier materials, which do not contribute to therapeutic activity but increase cost and toxicity risk. A better alternative may be "dual-functional" micellar carriers, in which the hydrophobic carrier material (conjugated to PEG) has intrinsic therapeutic activity that complements, or even synergizes with, the antitumor activity of the drug cargo. This review summarizes recent progress in the development of PEG-derivatized dual-functional nanomicelles and surveys the evidence of their feasibility and promise for cancer therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Baolin Guo, Xi’an Jiaotong University, China; Song Li, University of Pittsburgh, United States
This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology
Edited by: Ali H. Eid, American University of Beirut, Lebanon
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2019.00808